Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUINIDEX vs QUINORA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.
Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
Conversion and prevention of atrial fibrillation/flutter,Maintenance of sinus rhythm after cardioversion,Treatment of ventricular arrhythmias (off-label)
Treatment of atrial fibrillation and flutter,Ventricular arrhythmias,Off-label: Management of malaria (as quinine derivative)
Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.
325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.
Terminal elimination half-life is 6-8 hours in adults with normal renal and hepatic function; may be prolonged to 10-12 hours in congestive heart failure or hepatic impairment.
5-7 hours; prolonged in hepatic impairment (up to 12-15 hours) and in elderly patients.
Primarily hepatic via CYP3A4 (major) and CYP2C9 (minor) to active metabolites (3-hydroxyquinidine, quinidine-N-oxide); also renal excretion of unchanged drug (20%).
Primarily hepatic via CYP3A4; also metabolized by CYP2C9 and CYP2E1. Active metabolites include 3-hydroxyquinidine. Renal excretion of unchanged drug accounts for 10-20% of clearance.
Renal excretion accounts for approximately 20% unchanged drug; hepatic metabolism (primarily CYP3A4) accounts for 80% with metabolites excreted renally and biliarily; about 5% excreted in feces.
Primarily hepatic (biliary) excretion into feces (~80-90%); renal excretion of unchanged drug accounts for ~10-20%.
80-90% bound to plasma proteins: primarily albumin and alpha-1-acid glycoprotein.
90-95% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
2-4 L/kg; extensive tissue distribution with high affinity for myocardium (tissue-to-plasma ratio >10).
2.5-3.5 L/kg; extensive tissue distribution with high affinity for cardiac muscle.
70-80% for immediate-release oral; 50-70% for sustained-release formulations due to first-pass metabolism; absorption reduced by food.
Oral: ~70-80% (first-pass metabolism reduces bioavailability; food may decrease rate but not extent).
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours. Cr Cl 10-29 m L/min: administer 50% of normal dose every 8 hours. Cr Cl <10 m L/min: administer 50% of normal dose every 12 hours.
GFR 30-50 m L/min: reduce dose by 25%; GFR <30 m L/min: avoid use or prolong dosing interval to every 8 hours.
Child-Pugh class A: no adjustment. Child-Pugh class B: reduce dose by 50%; monitor levels. Child-Pugh class C: contraindicated or use with extreme caution; reduce dose by 75% with therapeutic drug monitoring.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Oral: 15-60 mg/kg/day in 4-5 divided doses; maximum single dose 600 mg. For chronic suppression: start 30 mg/kg/day in 4-5 divided doses.
10-15 mg/kg/dose orally every 4-6 hours; maximum 60 mg/kg/day.
Start at lower end of dosing range (200 mg every 8 hours) due to decreased hepatic and renal function; adjust based on plasma levels and QT interval monitoring.
Start at lowest effective dose; consider 325 mg every 6-8 hours due to increased risk of accumulation.
Increased mortality in treatment of non-life-threatening ventricular arrhythmias; proarrhythmic effects (torsades de pointes).
May cause potentially fatal ventricular arrhythmias (e.g., torsades de pointes) due to QT prolongation. Reserve for patients with life-threatening arrhythmias. Monitor ECG and serum electrolytes. Discontinue if QT interval >50% baseline or QRS duration increases >25%.
Proarrhythmia (torsades de pointes), hepatotoxicity, cinchonism, hypersensitivity reactions, worsening of heart failure, digitalis toxicity, incomplete AV block, electrolyte disturbances.
May cause cinchonism (tinnitus, headache, visual disturbances). Risk of QT prolongation and torsades de pointes, especially in patients with hypokalemia, bradycardia, or structural heart disease. Hemolytic anemia may occur in G6PD deficiency. Can exacerbate heart failure due to negative inotropic effects. Drug interactions: hepatic enzyme inducers/inhibitors, other QT-prolonging drugs.
Hypersensitivity to quinidine or cinchona alkaloids, complete AV block or severe intraventricular conduction defects, myasthenia gravis, history of thrombocytopenia with quinidine, concurrent use with drugs that prolong QT interval (unless absolutely necessary).
History of QT prolongation or torsades de pointes with quinidine. Myasthenia gravis (due to anticholinergic effects). Complete AV block without pacemaker. Known hypersensitivity (including thrombocytopenia). Major contraindication in malaria caused by Plasmodium falciparum with severe adverse reactions.
Grapefruit juice increases quinidine bioavailability and serum levels, raising toxicity risk. Avoid grapefruit and grapefruit juice. Alkaline foods (e.g., antacids, milk) may increase quinidine absorption. High-sodium diet may enhance potassium loss and worsen arrhythmias. Avoid excessive caffeine or stimulants.
Grapefruit juice increases quinidine levels; avoid concurrent use. Food does not affect absorption significantly; take with or without food. High-fat meals may delay absorption.
First trimester: Limited data, but quinidine crosses placenta. No clear increase in major malformations after first trimester exposure. Second and third trimesters: Risk of fetal QT prolongation, neonatal thrombocytopenia, and tachycardia. Fetal distress may occur. Avoid if alternative exists, but if needed, monitor fetal ECG and heart rate.
In first trimester, associated with increased risk of spontaneous abortion and congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may cause premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Quinidine is excreted into breast milk. M/P ratio reported as 0.57–0.78. Amount is low, but monitor infant for arrhythmias, bruising, and bleeding. Generally considered compatible with breastfeeding if maternal monitoring is done.
Excreted into breast milk; M/P ratio unknown. Due to risk of serious adverse reactions in nursing infants including kernicterus in neonates with G6PD deficiency, contraindicated during breastfeeding.
Increased volume of distribution may require dose increases. Protein binding decreases, potentially lowering total drug concentrations. Monitor free drug levels if possible. adjust dose based on therapeutic drug monitoring and clinical response. Close monitoring recommended.
Increased volume of distribution and renal clearance during pregnancy may require dose increase; therapeutic drug monitoring recommended to maintain efficacy.
Quinidine (as Quinidex) is a class Ia antiarrhythmic; monitor QRS and QT intervals due to risk of torsades de pointes. It also has anticholinergic properties, causing diarrhea in up to 50% of patients, which can be dose-limiting. Drug interactions are critical: quinidine inhibits CYP2D6, increasing levels of digoxin, warfarin, and many beta-blockers. Consider checking serum quinidine levels (therapeutic: 2-6 mcg/m L) and ECG if initiating or adjusting dose.
Quinora (quinidine) is a class Ia antiarrhythmic; monitor for QT prolongation and torsades de pointes. Use with caution in heart failure, renal impairment, and hepatic dysfunction. Check serum potassium and magnesium levels before initiation. Watch for cinchonism (tinnitus, headache, blurred vision) at high doses. Avoid use with other QT-prolonging drugs. Therapeutic drug monitoring is recommended (target 2-6 mcg/m L).
Take exactly as prescribed; do not double dose if missed.,Avoid grapefruit juice as it can increase quinidine levels and toxicity.,Report new or worsening palpitations, dizziness, syncope, or irregular heartbeat immediately.,May cause diarrhea; contact your prescriber if diarrhea becomes severe or persistent.,Quinidine can cause blurred vision, tinnitus, or headache; report these to your doctor.,Avoid over-the-counter medications without consulting your doctor (especially antacids, antihistamines, and cold remedies).
Take exactly as prescribed; do not skip doses or double up if missed.,Report any signs of allergic reaction (rash, fever, difficulty breathing) or unusual bleeding/bruising.,Avoid grapefruit juice as it may increase quinidine levels.,Contact your doctor if you experience dizziness, fainting, or palpitations.,Do not stop abruptly; taper as directed to avoid rebound arrhythmias.,Tell all healthcare providers you are taking quinidine.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUINIDEX vs QUINORA, answered by our medical review team.
QUINIDEX is a Antiarrhythmic Agent that works by Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.. QUINORA is a Antiarrhythmic Agent that works by Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUINIDEX and QUINORA depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUINIDEX is: Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.. The standard adult dose of QUINORA is: 325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUINIDEX and QUINORA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUINIDEX is classified as Category C. First trimester: Limited data, but quinidine crosses placenta. No clear increase in major malformations after first trimester exposure. Second and third trimesters: Risk of fetal Q. QUINORA is classified as Category C. In first trimester, associated with increased risk of spontaneous abortion and congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exp. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.